Displaying drugs 10601 - 10625 of 12564 in total
TZ-101
TZ-101 composes of GDP-L-fucose and fucosyltransferase VI
Investigational
Matched Description: … TZ-101 composes of [GDP-L-fucose] and fucosyltransferase VI …
Etesevimab
Etesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain.[L16651,L16661] Under the EUA granted in February 2021, etesevimab is used in combination with bamlanivimab to treat mild to moderate COVID-19 in adults and pediatric patients who...
Investigational
Matched Description: … [L40174] The EUA currently allows bamlanivimab and etesevimab for post-exposure prophylaxis of COVID- …
FP0011
FP0011 is a small molecule antiglutamatergic compound with symptomatic and disease modifying effects in a variety of neurological disorders (amyotrophic lateral sclerosis and Parkinson's disease). It acts on the presynaptic regulation of glutamate and shows strong neuroprotective properties.
Investigational
Matched Description: … It acts on the presynaptic regulation of glutamate and shows strong neuroprotective properties. ... small molecule antiglutamatergic compound with symptomatic and disease modifying effects in a variety of …
SBT-100
SBT-100 is an anti-signal transducer and activator of transcription 3 (STAT3) B VHH13 single-domain antibody (sdAb). It was granted orphan drug designation by the FDA for the treatment of pancreatic cancer and osteosarcoma.[L44131,L44136]
Investigational
Matched Description: … SBT-100 is an anti-signal transducer and activator of transcription 3 (STAT3) B VHH13 single-domain antibody ... It was granted orphan drug designation by the FDA for the treatment of pancreatic cancer and osteosarcoma …
SNS01-T
SNS01-T is a gene therapy nanoparticle. It is composed of three components: a B cell-specific plasmid expressing eIF5AK50R; an siRNA that targets the native eIF5A that promotes growth/anti-apoptosis of cancer cells; and polyethylenimine.
Investigational
Matched Description: … the native eIF5A that promotes growth/anti-apoptosis of cancer cells; and polyethylenimine. ... It is composed of three components: a B cell-specific plasmid expressing eIF5AK50R; an siRNA that targets …
BMN-351
BMN-351 is a fully modified 18-mer oligonucleotide with a TEG modification at its 5' end that binds to exon 51 of dystrophin pre-mRNA. It is under investigation for the treatment of Duchenne Muscular Dystrophy (DMD).
Investigational
Matched Description: … It is under investigation for the treatment of Duchenne Muscular Dystrophy (DMD). ... a fully modified 18-mer oligonucleotide with a TEG modification at its 5' end that binds to exon 51 of …
XTL-6865
XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein. It is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease.
Investigational
Matched Description: … XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis ... It is being developed to prevent HCV re-infection following a liver transplant and for the treatment of …
Dexpramipexole
Dexpramipexole is under investigation in clinical trial NCT01511029 (Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)).
Investigational
Matched Description: … the QRS Complex to the End of the T Wave Corrected for Heart Rate)). ... Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of …
Vercirnon
Vercirnon is a novel, orally active anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of IBD. It is under investigation in clinical trial NCT01611805 (Japanese Phase I of GSK1605786).
Investigational
Matched Description: … It is under investigation in clinical trial NCT01611805 (Japanese Phase I of GSK1605786). ... receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of …
Rexin G
Rexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene. It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. It is also being investigated for preventing SARSCOV-2 viral entry.
Investigational
Matched Description: … Rexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene ... It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. …
RGX-501
RGX-501 is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional copy of the human low-density lipoprotein receptor (LDLR) gene to liver cells. It is being investigated for the treatment of homozygous familial hypercholesterolemia.
Investigational
Matched Description: … is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional copy of ... It is being investigated for the treatment of homozygous familial hypercholesterolemia.[L46696] …
VTX-801
VTX-801 is a replication-deficient recombinant adeno-associated viral vector (rAAV) consisting of an AAV liver tropic capsid containing a single-stranded DNA genome carrying a shortened version of the ATP7B gene (ATP7B-minigene). It is being investigated in Wilson Disease.
Investigational
Matched Description: … VTX-801 is a replication-deficient recombinant adeno-associated viral vector (rAAV) consisting of an ... AAV liver tropic capsid containing a single-stranded DNA genome carrying a shortened version of the ATP7B …
Viralym-C
Viralym-C is an investigational T-cell immunotherapy developed by ViraCyte. It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes. It was granted FDA orphan designation in January 2017 and investigated for the treatment of CMV infection.[A260291, L47241]
Investigational
Matched Description: … It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes. ... It was granted FDA orphan designation in January 2017 and investigated for the treatment of CMV infection …
Sparteine
Sparteine is a plant alkaloid derived from Cytisus scoparius and Lupinus mutabilis which may chelate calcium and magnesium. It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. Sparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one...
Experimental
Withdrawn
Matched Description: … It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. ... Sparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one of the ... products that have been withdrawn or removed from the market for reasons of safety or effectiveness. …
Trefoil Factor 2
The trefoil factor 2 (TFF2) peptide is a low-molecular weight protein and one of the three trefoil-motif-containing proteins. They are expressed predominantly in gastric tissues with the source for them being predominantly stromal cells, although expression of TFF2 mRNA transcripts also occurs with tissue macrophages. The peptides themselves are most...
Investigational
Matched Description: … in gastric tissues with the source for them being predominantly stromal cells, although expression of ... The trefoil factor 2 (TFF2) peptide is a low-molecular weight protein and one of the three trefoil-motif-containing ... The peptides themselves are most abundant in mucous cells of the gastric mucosa with TFF2 being detected …
Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells
ORBCEL-C™ is the trade name of a product composed of highly purified stromal cells derived from the human umbilical cord. The isolated cells are expanded in culture and are able to be used allogenically -- meaning that one donor’s cells can be given to other unrelated patients. These cells are...
Investigational
Matched Description: … ORBCEL-C™ is the trade name of a product composed of highly purified stromal cells derived from the human ... Enrichment of CD362 expression in MSCs is being investigated for its role in immune modulation of injured ... Regarding the modifications of these UC-MSCs, CD362, also known as syndecan-2, is a surface marker identified …
NS-398
NS-398 is a COX-2 inhibitor. It was developed as part of the mechanistic study of the cyclooxygenases.
Experimental
Matched Description: … It was developed as part of the mechanistic study of the cyclooxygenases. …
AI-128
AI-128 is the first human demonstration of sustained release drug administration in the lung. AI-128 consists of slowly dissolving microspheres designed to control where drug particles go in the lung and how quickly they release their drug.
Investigational
Matched Description: … AI-128 is the first human demonstration of sustained release drug administration in the lung. ... AI-128 consists of slowly dissolving microspheres designed to control where drug particles go in the …
Osoresnontrine
Osoresnontrine is under investigation in clinical trial NCT02281773 (A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.).
Investigational
Matched Description: … investigation in clinical trial NCT02281773 (A Study to Investigate the Efficacy, Safety and Tolerability of ... Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia …
Artefenomel
Artefenomel has been investigated for the treatment of Malaria.
Investigational
Matched Description: … Artefenomel has been investigated for the treatment of Malaria. …
Pyronaridine
Pyronaridine has been investigated for the treatment of Malaria.
Investigational
Matched Description: … Pyronaridine has been investigated for the treatment of Malaria. …
Enecadin
Enecadin has been investigated for the treatment of Stroke.
Investigational
Matched Description: … Enecadin has been investigated for the treatment of Stroke. …
SB-218078
SB-218078 is a specific inhibitor of CHK1.
Investigational
Matched Description: … SB-218078 is a specific inhibitor of CHK1.[A253117] …
ATN-161
ATN-161 is a non-RGD based integrin binding peptide targeting alpha-5 beta-1 and alpha-v beta-3. It inhibits the migration and adhesion of particular integrins on activated endothelial cells that play a critical role in tumor angiogenesis. This approach targeting both the tumor vasculature and the cancer cells themselves, may be effective...
Investigational
Matched Description: … to extend to a variety of cancers. ... Since the expression of alpha(5)beta(1) integrin by cancer cells and the role of this molecule in tumor ... angiogenesis is similar across a range of different cancers, the therapeutic benefit of ATN-161 is expected …
N-(2-Aminoethyl)-1-aziridineethanamine
First described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease and its activity against Severe Acute Respiratory Syndrome (SARS).
Experimental
Displaying drugs 10601 - 10625 of 12564 in total